Scarica l'app Stockscreener
241.44
1.85%
4.39
Pre-mercato:
237.00
-4.44
-1.84%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VEEV Giù?
Forum
Previsione
Precedente Chiudi:
$237.05
Aprire:
$238
Volume 24 ore:
2.26M
Relative Volume:
1.85
Capitalizzazione di mercato:
$38.62B
Reddito:
$2.75B
Utile/perdita netta:
$714.14M
Rapporto P/E:
55.76
EPS:
4.33
Flusso di cassa netto:
$1.09B
1 W Prestazione:
+1.88%
1M Prestazione:
+10.75%
6M Prestazione:
+2.08%
1 anno Prestazione:
+18.48%
Intervallo 1D:
$225.51
$241.78
Intervallo di 1 settimana:
$225.51
$242.00
Portata 52W:
$170.25
$258.93
Veeva Systems Inc Stock (VEEV) Company Profile
Nome
Veeva Systems Inc
Settore
Industria
Telefono
925-452-6500
Indirizzo
4280 HACIENDA DRIVE, PLEASANTON, CA
Confronta VEEV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
241.44 | 38.62B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
61.04 | 11.14B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
62.69 | 9.36B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
96.66 | 7.91B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
40.30 | 7.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-23 | Downgrade | Goldman | Buy → Sell |
| 2024-12-20 | Iniziato | Stephens | Overweight |
| 2024-12-04 | Iniziato | Mizuho | Outperform |
| 2024-11-19 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-08 | Iniziato | Exane BNP Paribas | Outperform |
| 2024-08-27 | Reiterato | Citigroup | Buy |
| 2024-07-09 | Iniziato | BTIG Research | Buy |
| 2023-10-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-10-13 | Iniziato | Jefferies | Buy |
| 2023-06-28 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Truist | Buy → Hold |
| 2023-02-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-04 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-12-06 | Iniziato | Cowen | Market Perform |
| 2022-12-02 | Reiterato | Needham | Buy |
| 2022-10-31 | Iniziato | Wells Fargo | Equal Weight |
| 2022-10-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-07-27 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | Goldman | Buy |
| 2022-06-21 | Ripresa | Guggenheim | Buy |
| 2022-03-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2022-01-07 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-06 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Ripresa | Stifel | Buy |
| 2021-09-02 | Reiterato | BofA Securities | Buy |
| 2021-09-02 | Reiterato | JMP Securities | Mkt Outperform |
| 2021-09-02 | Reiterato | Needham | Buy |
| 2021-09-02 | Reiterato | UBS | Neutral |
| 2021-07-21 | Iniziato | Cowen | Outperform |
| 2021-03-31 | Aggiornamento | UBS | Sell → Neutral |
| 2021-01-07 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2020-12-09 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-10-14 | Ripresa | UBS | Sell |
| 2020-08-28 | Reiterato | Needham | Buy |
| 2020-07-23 | Iniziato | FBN Securities | Outperform |
| 2020-07-07 | Iniziato | Stephens | Overweight |
| 2020-06-08 | Iniziato | Citigroup | Buy |
| 2020-05-29 | Reiterato | Needham | Buy |
| 2020-04-13 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-14 | Iniziato | Piper Sandler | Overweight |
| 2020-01-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-27 | Reiterato | Canaccord Genuity | Hold |
| 2019-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-08-28 | Reiterato | Needham | Buy |
| 2019-06-07 | Iniziato | Goldman | Neutral |
| 2019-05-30 | Reiterato | BofA/Merrill | Buy |
| 2019-05-30 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2019-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-04-17 | Reiterato | Needham | Buy |
| 2019-02-27 | Reiterato | Needham | Buy |
Mostra tutto
Veeva Systems Inc Borsa (VEEV) Ultime notizie
For Third Year in a Row, Veeva MedTech Recognized as Best Overall MedTech Software - Veeva
Veeva Systems (VEEV) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Veeva to Release Fiscal 2026 First Quarter Results on May 28, 2025 | VEEV Stock News - GuruFocus
Veeva to Release Fiscal 2026 First Quarter Results on May 28, 2025 - Yahoo Finance
eClinical Solutions Market Size to Lead USD 40,500 Million by 2034, Growth in the Biopharmaceutical and Pharmaceutical Industry - GlobeNewswire Inc.
Life Sciences Leaders Advance Unified Engagement at Veeva Commer - GuruFocus
Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit | VEEV Stock News - GuruFocus
Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit - marketscreener.com
Advancing the Future of Unified Engagement - Veeva
Veeva: Our 2025 Software Pick Just Keeps Winning (NYSE:VEEV) - Seeking Alpha
Connecting Quality and Regulatory for Data-Driven Change Control - Veeva
2024 Veeva Commercial Summit | Veeva - Veeva
June 2026 Options Now Available For Veeva Systems (VEEV) - Nasdaq
Veeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors - Yahoo
Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know - MSN
Here's How Much $100 Invested In Veeva Systems 10 Years Ago Would Be Worth Today - Benzinga
Veeva Systems (NYSE:VEEV) Unveils Veeva AI To Boost Productivity In Life Sciences - Yahoo Finance
Werner Engelbrecht - AI Business
Veeva Systems (VEEV) Introduces Veeva AI to Enhance Life Science - GuruFocus
Veeva Systems Introduces Veeva AI - Contract Pharma
Announcing Veeva AI | VEEV Stock News - GuruFocus
Veeva Systems (VEEV) Introduces Veeva AI to Enhance Life Sciences Automation | VEEV Stock News - GuruFocus
Announcing Veeva AI - marketscreener.com
Veeva's Game-Changing AI Initiative Promises to Revolutionize Life Sciences Operations by 2025 - Stock Titan
Here's Why You Should Add Veeva Stock to Your Portfolio Now - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Peering Into Veeva Systems's Recent Short Interest - Benzinga
Veeva (VEEV) Price Target Trimmed by Piper Sandler Amid Industry Challenges | VEEV Stock News - GuruFocus
Zacks Industry Outlook Highlights Veeva Systems, Hims & Hers Health and Butterfly Network - Yahoo Finance
Life Science Data Needs an Upgrade: Veeva Has Answers - Fierce Pharma
Here is What to Know Beyond Why Veeva Systems Inc. (VEEV) is a Trending Stock - MSN
Wall Street Bulls Look Optimistic About Veeva (VEEV): Should You Buy? - Yahoo Finance
Veeva Systems: Substantially Overvalued As Growth Slows (NYSE:VEEV) - Seeking Alpha
Veeva Systems (NYSE:VEEV) Partners With Flatiron To Enhance Clinical Trial Data Efficiency - Yahoo Finance
Flatiron Health Joins Veeva’s Product Partner Program to Accelerate Oncology Clinical Research - Business Wire
Q4 Earnings Outperformers: Veeva Systems (NYSE:VEEV) And The Rest Of The Vertical Software Stocks - Yahoo Finance
Veeva Systems (VEEV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Veeva Systems’ chief customer officer sells $265,168 in stock By Investing.com - Investing.com India
Veeva Systems’ chief customer officer sells $265,168 in stock - Investing.com
4 Ways Top Sponsors Build Strong and Sustainable Site Relationships - Veeva
Investors Interested In Veeva Systems Inc.'s (NYSE:VEEV) Earnings - simplywall.st
Improve Safety Outputs, Oversight, and Data Quality with In-house Pharmacovigilance Solution - Veeva
B. Braun Transforms Global Clinical Trial Management for Digital Excellence - Veeva
Veeva (VEEV) Moves 3.7% Higher: Will This Strength Last? - Nasdaq
eClinical Solutions Market Top PlayersMedidata, Veeva Systems, Iqvia Inc., Icon Plc, Signant Health. - openPR.com
ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva
Veeva Systems director Timothy Cabral sells $841,734 in stock By Investing.com - Investing.com Canada
Veeva Systems director Timothy Cabral sells $841,734 in stock - Investing.com
Veeva Systems Inc Azioni (VEEV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.13%
2.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):